Neurogenic inflammation, the pathogenesis of many diseases

OLYS Pharma is developing a technological platform, protected by patents, which targets innate immune pathways capable of breaking the pro-inflammatory vicious circle of neurogenic inflammation, considered to be the pathogenesis of many diseases. This is a significant step forward for the hundreds of millions of patients suffering from pathologies causing chronic inflammatory pain.